Drug Profile
Microbiome-based therapeutics - Ferring/MetaboGen
Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator MetaboGen
- Developer Ferring Pharmaceuticals
- Class Bacteria; Probiotics
- Mechanism of Action Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Intrahepatic cholestasis
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for clinical-Phase-Unknown development in Intrahepatic-cholestasis in Sweden
- 28 Jan 2020 No recent reports of development identified for clinical-Phase-Unknown development in Intrahepatic-cholestasis(Prevention) in Sweden
- 06 Dec 2016 Clinical trials in Intrahepatic cholestasis (Prevention) in Sweden